Genflow Biosciences Plc (WQ5)

Overview

Genflow Biosciences plc operates as a pioneering biotechnology enterprise within the United Kingdom and Belgium, primarily focusing on the development of biological interventions aimed at confronting the challenges of ageing. The company is dedicated to finding solutions that not only slow down and halt the ageing process but also aim to reduce the incidence of age-related diseases, thereby increasing the health span. Incorporated in 2021, and with its headquarters in London, Genflow Biosciences is at the forefront of leveraging advanced biotechnology to extend quality life years.

Products and Services

• GF-1002:

A leading compound in Genflow's portfolio, GF-1002 represents a breakthrough in gene therapy, utilizing an adeno-associated viral vector for intravenous infusion. This innovative therapy is focused on addressing core issues related to the biological processes of ageing at a genetic level, offering a promising avenue for extending health spans.

• GF-3001:

This product is designed as a topical solution targeting the skin, delivering SIRT6 directly. By focusing on one of the most visible signs of ageing, GF-3001 seeks to provide a non-invasive mode of intervention to restore skin health and vitality, thereby contributing to improved overall well-being and appearance.

• GF-4001:

In an innovative expansion beyond human healthcare, GF-4001 is being developed for veterinary use, targeting the anti-ageing market for non-human life forms. This non-human pipeline project underscores Genflow Biosciences' commitment to extending its cutting-edge ageing intervention technologies across a broad spectrum of biological entities to increase their health span and quality of life.